Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.35 |
| ▸ | NAMPT | P43490 | 10/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765520 | 0.83 | NTRK1 (0.41) | NTRK1NAMPTNTRK3 | |
| SCHEMBL30765840 | 0.83 | NAMPT (0.38) | NTRK1IRAK4NAMPTNTRK3CYP2C9 | |
| SCHEMBL30765852 | 0.78 | NTRK1 (0.38) | NTRK1NAMPTNTRK3MEN1KMT2A | |
| SCHEMBL30765874 | 0.77 | NTRK1 (0.41) | NTRK1NAMPTNTRK3 | |
| SCHEMBL30765928 | 0.76 | DGAT2 (0.44) | NTRK1NTRK3LMNADGAT2 | |
| SCHEMBL30765865 | 0.72 | NTRK1 (0.37) | NTRK1NAMPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30765506 | 0.71 | NTRK1 (0.51) | NTRK1NTRK3 | |
| SCHEMBL30765715 | 0.69 | ATM (0.40) | MEN1LMNAKMT2ASMN1; SMN2DGAT2 | |
| SCHEMBL30765718 | 0.69 | NTRK1 (0.45) | NTRK1NTRK3MEN1KMT2A | |
| SCHEMBL32680681 | 0.68 | ALDH1A1 (0.50) | NTRK1NAMPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |